Two Sigma Advisers
SLN

Two Sigma Advisers’s Silence Therapeutics SLN Stock Holding History

Two Sigma Advisers’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,900
Closed -$96.7K – 1817
2025
Q4 		$96.7K Sell
15,900
-26,700
-63% -$171K ﹤0.01% 2231
2025
Q3 		$221K Buy
42,600
+3,000
+8% +$16.7K ﹤0.01% 2097
2025
Q2 		$230K Sell
39,600
-9,600
-20% -$41.2K ﹤0.01% 2066
2025
Q1 		$139K Sell
49,200
-49,600
-50% -$242K ﹤0.01% 2201
2024
Q4 		$680K Buy
98,800
+15,500
+19% +$200K ﹤0.01% 1644
2024
Q3 		$1.51M Buy
83,300
+7,100
+9% +$132K ﹤0.01% 1222
2024
Q2 		$1.45M Sell
76,200
-1,200
-2% -$25.5K ﹤0.01% 1370
2024
Q1 		$1.67M Buy
+77,400
New +$1.68M ﹤0.01% 1316

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Two Sigma Advisers's SLN Position: Q1 2026 in Review

Two Sigma Advisers sold out of Silence Therapeutics (SLN) in Q1 2026, closing a stake of 15,900 shares — an estimated $96.7K sold.

Two Sigma Advisers first reported a position in SLN in Q1 2024 and held it in 8 quarters. The position peaked at $1.67M in Q1 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Two Sigma Advisers reported no remaining Silence Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 15,900 Silence Therapeutics shares in Q1 2026, an estimated $96.7K.
  • Two Sigma Advisers first reported a position in Silence Therapeutics in Q1 2024 and held it in 8 quarters.
  • Two Sigma Advisers's Silence Therapeutics position peaked at $1.67M in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.